Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus letrozole for exemestane-resistant postmenopausal recurrent or metastatic breast cancer
ChiCTR-OPC-14005627Phase 4Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Dec 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of everolimus and letrozole in breast cancer, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-free survival. Planned start Dec 2014; status: not yet recruiting.
02
Drugs
everolimusletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-OPC-14005627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-14005627.